ERBB2 and breast carcinoma: A total of 5610 early breast cancer patients were included in the analysis: 1066 patients with HER2-0, 3209 with HER2-Low, 1335 with HER2-Positive CNB findings, 909 patients with HER2-0, 3320 with HER2-Low and 1381 with HER2-Positive SES findings (Figure 1).